Mark J. Ratain to Disease Progression
This is a "connection" page, showing publications Mark J. Ratain has written about Disease Progression.
Connection Strength
0.309
-
Estimation of renal cell carcinoma treatment effects from disease progression modeling. Clin Pharmacol Ther. 2013 Apr; 93(4):345-51.
Score: 0.078
-
Why RECIST works and why it should stay--reply to counterpoint. Cancer Res. 2012 Oct 15; 72(20):5158.
Score: 0.076
-
Evaluating the activity of temsirolimus in neuroendocrine cancer. Br J Cancer. 2007 Jan 15; 96(1):177; author reply 178-9.
Score: 0.051
-
Measuring response in a post-RECIST world: from black and white to shades of grey. Nat Rev Cancer. 2006 05; 6(5):409-14.
Score: 0.049
-
Randomized discontinuation design: application to cytostatic antineoplastic agents. J Clin Oncol. 2002 Nov 15; 20(22):4478-84.
Score: 0.039
-
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010 Oct 28; 363(18):1693-703.
Score: 0.017